scispace - formally typeset
A

Alan Huang

Researcher at Novartis

Publications -  63
Citations -  6110

Alan Huang is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & PI3K/AKT/mTOR pathway. The author has an hindex of 27, co-authored 52 publications receiving 5026 citations.

Papers
More filters
Journal ArticleDOI

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

TL;DR: The biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models and behaves synergistically when combined with either targeted agentssuch as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.
Journal ArticleDOI

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

TL;DR: BRAF(V600E) drives tumors by dysregulating ERK signaling, and its activation is Ras independent and it signals as a RAF-inhibitor-sensitive monomer, and combined inhibition results in enhancement of ERK pathway inhibition and antitumor activity.
Journal ArticleDOI

Single-vector inducible lentiviral RNAi system for oncology target validation.

TL;DR: The versatile and robust inducible lentiviral RNAi system reported herein can serve as a powerful tool to rapidly reveal tumor cell dependence.